AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20191783 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of desaturation while in the PACU
Number of subjects: 102
Study 20191783 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval between last dose of relaxant and arrival in PACU
Number of subjects: 102
Study 18602729 — intervention group
Group type: EXPERIMENTAL
Intervention: Influvac
Number of subjects: 840
Study 18602729 — intervention group
Group type: EXPERIMENTAL
Intervention: Agrippal
Number of subjects: 840
Study 15894598 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-gamma1b
Number of subjects: 315
Study 15894598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 12025888 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-min infusion of topotecan (1.5 mg/m2/d for 5 days of a 21-day course)
Number of subjects: 12
Study 12025888 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-min infusion of topotecan
Number of subjects: 12
Study 12033124 — intervention group
Group type: EXPERIMENTAL
Intervention: Colour cues applied to a free-standing transfer pole for one month in Groups 1 and 2.
Number of subjects: 30
Study 12033124 — intervention group
Group type: COMPARATOR
Intervention: Control group with no colour cues applied, views sampled only on exit.
Number of subjects: 30
Study 7673536 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-limited psychotherapy (TLP)
Number of subjects: 33
Study 7673536 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed TLP for 3 months)
Number of subjects: 33
Study 7673536 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (TLP)
Number of subjects: 33
Study 7673536 — intervention group
Group type: COMPARATOR
Intervention: Control group (after waiting)
Number of subjects: 33
Study 2177970 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMH)
Number of subjects: 28
Study 2177970 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 28
Study 7077546 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (up to 80 W on a bicycle ergometer)
Number of subjects: 22
Study 7077546 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-standardized interview
Number of subjects: 22
Study 7077546 — intervention group
Group type: EXPERIMENTAL
Intervention: Slide viewing (showing parents and marriage partners)
Number of subjects: 22
Study 7077546 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand ergometer test
Number of subjects: 22
Study 7077546 — intervention group
Group type: COMPARATOR
Intervention: All experimental conditions
Number of subjects: 22
Study 31477187 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic measurements
Number of subjects: 155
Study 31477187 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic measurements (limited to 86 patients with similar sedation)
Number of subjects: 155
Study 31477187 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional echocardiographic measures
Number of subjects: 155
Study 28284221 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal contraceptive method (DMPA, oral pills, norplant)
Number of subjects: 807
Study 28284221 — intervention group
Group type: EXPERIMENTAL
Intervention: Existing users of hormonal contraceptives
Number of subjects: 807
Study 28284221 — intervention group
Group type: EXPERIMENTAL
Intervention: New users of hormonal contraceptives
Number of subjects: 807
Study 28284221 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger women (≤30 years)
Number of subjects: 807
Study 28284221 — intervention group
Group type: EXPERIMENTAL
Intervention: Women not using contraceptives at baseline due to lack of access or money, breastfeeding, or other reasons
Number of subjects: 807
Study 25962707 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 2079
Study 25962707 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 2079
Study 25962707 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 2079
Study 25962707 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c (impaired fasting glucose)
Number of subjects: 2079
Study 25962707 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c (normal glucose)
Number of subjects: 2079
Study 25962707 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c threshold of 40 mmol/mol (5.8%)
Number of subjects: 2079
Study 23585423 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril at 0.4 mg/kg/day for 1 year
Number of subjects: 41
Study 23585423 — intervention group
Group type: COMPARATOR
Intervention: No enalapril (control)
Number of subjects: 41
Study 21436391 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 8
Study 21436391 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 8
Study 19738137 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary vitamin K-guided strategy
Number of subjects: 132
Study 19738137 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 132
Study 17694046 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraligamental injection (ITR)
Number of subjects: 54
Study 17694046 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration injection (IFL)
Number of subjects: 54
Study 17694046 — intervention group
Group type: COMPARATOR
Intervention: No local anaesthetic (NLA)
Number of subjects: 54
Study 15037668 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous apomorphine therapy at a rate of 4 mg/h
Number of subjects: 9
Study 15037668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal apomorphine (2 to 5 mg per inhalation)
Number of subjects: 9
Study 15037668 — intervention group
Group type: COMPARATOR
Intervention: 3 mg subcutaneous apomorphine
Number of subjects: 9
Study 15037668 — intervention group
Group type: COMPARATOR
Intervention: 30 mg sublingual apomorphine
Number of subjects: 9
Study 15037668 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg rectal apomorphine suppository
Number of subjects: 9
Study 11232013 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 2 mg bd
Number of subjects: 493
Study 11232013 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg bd
Number of subjects: 493
Study 11232013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493
Study 10689659 — intervention group
Group type: EXPERIMENTAL
Intervention: Active electrical stimulation
Number of subjects: 265
Study 10689659 — intervention group
Group type: EXPERIMENTAL
Intervention: Most effective group
Number of subjects: 265
Study 10689659 — intervention group
Group type: COMPARATOR
Intervention: Inactive groups (placebo)
Number of subjects: 265
Study 7817151 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent teeth brushing and use of fluoride toothpaste
Number of subjects: 671
Study 7817151 — intervention group
Group type: COMPARATOR
Intervention: Less frequent teeth brushing and less use of fluoride toothpaste
Number of subjects: 671
Study 3165190 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% CMCP (2 microliters, replaced on days 3 and 7)
Number of subjects: 15
Study 3165190 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% CMCP (2 microliters, replaced on days 1 and 7)
Number of subjects: 15
Study 3165190 — intervention group
Group type: COMPARATOR
Intervention: Chemomechanical preparation (3% H2O2 and 5.25% NaOCl as irrigants, no intracanal medication)
Number of subjects: 15
Study 3165190 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% CMCP (2 microliters)
Number of subjects: 15
Study 3165190 — intervention group
Group type: COMPARATOR
Intervention: Chemomechanical preparation
Number of subjects: 15
Study 29600670 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic group
Number of subjects: 49
Study 29600670 — intervention group
Group type: COMPARATOR
Intervention: Conventional section group
Number of subjects: 49
Study 27842579 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy (OT) before surgical consultation
Number of subjects: 180
Study 27842579 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 180
Study 25341453 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI-guided microsurgery
Number of subjects: 600
Study 25341453 — intervention group
Group type: COMPARATOR
Intervention: standard microsurgery
Number of subjects: 600
Study 23519055 — intervention group
Group type: EXPERIMENTAL
Intervention: High TYRP1/S100B mRNA ratio
Number of subjects: 104
Study 21358087 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-HT (Radiation Therapy with Hyperthermia)
Number of subjects: 56
Study 21358087 — intervention group
Group type: COMPARATOR
Intervention: RT alone (Radiation Therapy)
Number of subjects: 56
Study 21358087 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-HT
Number of subjects: 56
Study 21358087 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 56
Study 18855232 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA-based evaluation forms
Number of subjects: 176
Study 18855232 — intervention group
Group type: COMPARATOR
Intervention: Printed evaluation forms
Number of subjects: 176
Study 17596638 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning or afternoon bright light exposure for 1 hr daily (Monday‐Friday) for 10 weeks
Number of subjects: 0
Study 17596638 — intervention group
Group type: COMPARATOR
Intervention: Usual indoor light
Number of subjects: 0
Study 12569202 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 38
Study 12569202 — intervention group
Group type: EXPERIMENTAL
Intervention: N-HRT
Number of subjects: 38
Study 10687880 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT group: Sequential combination of 2 mg estradiol valerate and 1 mg cyproterone acetate with or without vitamin D3 (100-300 IU/day) + calcium lactate (500 mg/day) (n = 232)
Number of subjects: 464
Study 10687880 — intervention group
Group type: COMPARATOR
Intervention: Non-HRT group: Calcium lactate (500 mg/day) alone or in combination with vitamin D3 (100-300 IU/day) (n = 232)
Number of subjects: 464
Study 10687880 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HRT and non-HRT)
Number of subjects: 464
Study 9210905 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG (intravesical instillation)
Number of subjects: 0
Study 9210905 — intervention group
Group type: EXPERIMENTAL
Intervention: BLP (lactobacillus casei preparation)
Number of subjects: 0
Study 9210905 — intervention group
Group type: EXPERIMENTAL
Intervention: Bropirimine (interferon inducer)
Number of subjects: 0
Study 8398322 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (3 doses of 8 mg IV at 0, 4, and 8 hours)
Number of subjects: 0
Study 8398322 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (3 mg/kg IV loading dose followed by 0.5 mg/kg/h for 8 hours)
Number of subjects: 0
Study 3081361 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG) 80 mg aerosolized
Number of subjects: 6
Study 3081361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31729930 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (participants declined intervention)
Number of subjects: 15
Study 30257802 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar (2.5 mg orally daily for 12 weeks)
Number of subjects: 65
Study 30257802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 30257802 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 65
Study 27282594 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial ESWT with 2000 shock waves/session of 0.2 mJ/mm(2) (n=20)
Number of subjects: 40
Study 27282594 — intervention group
Group type: COMPARATOR
Intervention: Local methylprednisolone injections (n=20)
Number of subjects: 40
Study 24676373 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (Continuous Positive Airway Pressure) at 6 cmH2O for 30 min
Number of subjects: 23
Study 24676373 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo at 0-1 cmH2O)
Number of subjects: 23
Study 22295869 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 20 mg/kg PO q8h for 16 weeks
Number of subjects: 34
Study 22295869 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 34
Study 22295869 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 34
Study 22295869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 20738476 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially funded trials (pharmaceutical companies)
Number of subjects: 105
Study 20738476 — intervention group
Group type: COMPARATOR
Intervention: Non-commercial trials
Number of subjects: 105
Study 19255990 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen suspension (10, 5, 5 mg/kg every 24 hours)
Number of subjects: 62
Study 19255990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 19255990 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen suspension
Number of subjects: 62
Study 16186612 — intervention group
Group type: EXPERIMENTAL
Intervention: Criteria-based learning method
Number of subjects: 83
Study 16186612 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical-research-and-experience-based learning method
Number of subjects: 83
Study 16186612 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study 12538432 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 10
Study 12538432 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate infusion
Number of subjects: 10
Study 10391155 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision (TME) with preoperative radiotherapy
Number of subjects: 500
Study 10391155 — intervention group
Group type: COMPARATOR
Intervention: Total mesorectal excision (TME) without preoperative radiotherapy
Number of subjects: 500
Study 9014674 — intervention group
Group type: COMPARATOR
Intervention: Stripping of the long saphenous vein
Number of subjects: 80
Study 9014674 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential avulsion of the long saphenous vein
Number of subjects: 80
Study 1345141 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 28
Study 1345141 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 28
Study 6435067 — intervention group
Group type: EXPERIMENTAL
Intervention: tinnitus masker
Number of subjects: 34
Study 6435067 — intervention group
Group type: EXPERIMENTAL
Intervention: tinnitus instrument (a combination device consisting of a tinnitus masker and a hearing aid)
Number of subjects: 34
Study 6435067 — intervention group
Group type: EXPERIMENTAL
Intervention: hearing aid
Number of subjects: 34
Study 6435067 — intervention group
Group type: COMPARATOR
Intervention: conventional environmental controls
Number of subjects: 34
Study 31381593 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 300
Study 31381593 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 300
Study 30001740 — intervention group
Group type: EXPERIMENTAL
Intervention: DMARD treatment (starting with methotrexate monotherapy with prednisolone bridging)
Number of subjects: 217
Study 30001740 — intervention group
Group type: COMPARATOR
Intervention: ACPA reactivity-positive patients
Number of subjects: 217
Study 30001740 — intervention group
Group type: EXPERIMENTAL
Intervention: ACPA reactivity levels
Number of subjects: 217
Study 26511599 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 8561
Study 26511599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8561
Study 24812043 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg or 1.25 mg
Number of subjects: 0
Study 24812043 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular interferon β‐1a (IFNβ‐1a)
Number of subjects: 0
Study 22421598 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro mix 25 (LM25)
Number of subjects: 80
Study 22421598 — intervention group
Group type: COMPARATOR
Intervention: Glargine
Number of subjects: 80
Study 21045965 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponseti methods (PCG)
Number of subjects: 105
Study 21045965 — intervention group
Group type: COMPARATOR
Intervention: Extensive soft tissue surgery (NPCG)
Number of subjects: 105
Study 18809617 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cisplatin and vinorelbine
Number of subjects: 482
Study 18809617 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 482
Study 16296571 — intervention group
Group type: EXPERIMENTAL
Intervention: Pager intervention (7 weeks)
Number of subjects: 63
Study 16296571 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (baseline and post-pager phase)
Number of subjects: 63
Study 16296571 — intervention group
Group type: COMPARATOR
Intervention: Baseline (2 weeks)
Number of subjects: 63
Study 16296571 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-pager phase (2 weeks)
Number of subjects: 63
Study 11990517 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-assessed quality of life parameters (toxicity and physical performance)
Number of subjects: 0
Study 11990517 — intervention group
Group type: EXPERIMENTAL
Intervention: QLQ-C30 nausea/vomiting and diarrhea scales
Number of subjects: 0
Study 11990517 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple linear regression analysis
Number of subjects: 0
Study 9485087 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg/day oral type II collagen (CII)
Number of subjects: 274
Study 9485087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study 9485087 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg/day oral type II collagen (CII)
Number of subjects: 274
Study 9485087 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg/day oral type II collagen (CII)
Number of subjects: 274
Study 9485087 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,500 microg/day oral type II collagen (CII)
Number of subjects: 274
Study 7894459 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction with an attractive male partner
Number of subjects: 0
Study 7894459 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction with an attractive female partner
Number of subjects: 0
Study 7894459 — intervention group
Group type: COMPARATOR
Intervention: No-encounter control situation
Number of subjects: 0
Study 2548552 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (5 mg oral)
Number of subjects: 7
Study 2548552 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin I (control)
Number of subjects: 7
Study 2548552 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin I (after cilazapril)
Number of subjects: 7
Study 811302 — intervention group
Group type: EXPERIMENTAL
Intervention: Interparietal instillation of povidone-iodine
Number of subjects: 0
Study 811302 — intervention group
Group type: COMPARATOR
Intervention: Untreated, randomized, matched controls
Number of subjects: 0
Study 30883882 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium, vitamin D, and genistein
Number of subjects: 2
Study 30883882 — intervention group
Group type: COMPARATOR
Intervention: Calcium and vitamin D
Number of subjects: 2
Study 28086917 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (up to 1 g by mouth twice daily)
Number of subjects: 119
Study 28086917 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol
Number of subjects: 119
Study 28086917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 26338810 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25/5 mg
Number of subjects: 281
Study 23632318 — intervention group
Group type: EXPERIMENTAL
Intervention: Defunctioning stoma (DSCA: 70%)
Number of subjects: 1880
Study 23632318 — intervention group
Group type: COMPARATOR
Intervention: Defunctioning stoma (TME-trial: 57%)
Number of subjects: 1880
Study 23632318 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastomotic leakage (DSCA: 12.1%)
Number of subjects: 1880
Study 23632318 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative mortality (DSCA: 1.1%)
Number of subjects: 1880
Study 23632318 — intervention group
Group type: COMPARATOR
Intervention: Postoperative mortality (TME-trial: 3.9%)
Number of subjects: 1880
Study 21318928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural health-promotion intervention
Number of subjects: 1057
Study 21318928 — intervention group
Group type: COMPARATOR
Intervention: HIV/STD risk-reduction intervention (Control)
Number of subjects: 1057
Study 19958431 — intervention group
Group type: EXPERIMENTAL
Intervention: Jessner's solution peel
Number of subjects: 45
Study 19958431 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid peel 20%
Number of subjects: 45
Study 19958431 — intervention group
Group type: COMPARATOR
Intervention: Topical hydroquinone 2% and kojic acid
Number of subjects: 45
Study 17063961 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-based risk awareness and perception training program
Number of subjects: 48
Study 17063961 — intervention group
Group type: COMPARATOR
Intervention: Untrained novice drivers
Number of subjects: 48
Study 10545589 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (group I, 182 infants)
Number of subjects: 371
Study 10545589 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group II, 189 infants)
Number of subjects: 371
Study 9074278 — intervention group
Group type: EXPERIMENTAL
Intervention: Microstop-treated bedding (Group 1)
Number of subjects: 71
Study 9074278 — intervention group
Group type: COMPARATOR
Intervention: Conventional bedding (Group 2)
Number of subjects: 71
Study 9074278 — intervention group
Group type: COMPARATOR
Intervention: Old bedding (Group 3)
Number of subjects: 71
Study 1715809 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% gamma‐BHC emulsion at 10.0 ml
Number of subjects: 1527
Study 1715809 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% gamma‐BHC emulsion at 5.0 ml
Number of subjects: 1527
Study 1715809 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% gamma‐BHC emulsion at 2.5 ml
Number of subjects: 1527
Study 1715809 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall infestation rate 5 months after treatment
Number of subjects: 1527
Study 6612232 — intervention group
Group type: EXPERIMENTAL
Intervention: Vas occlusion by tantalum clips without transection of the vasa
Number of subjects: 68